Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis

• DOI: 10.1111/all.14902
• Publication Date: 2021-05-12T14:49:59Z
• Authors: Giorgio Walter Ca...; Tim W. Harrison; Pascal Chanez; Francesco Menzella; Renaud Louis; Borja G. Cosio; Njira L. Lugogo; Arjun Mohan; Annie Burden; Esther Garcia Gil
• Keywords: Benralizumab

Clinically meaningful improvement in the Sino-Nasal Outcome Test-22 (SNOT-22) was observed patients with severe, eosinophilic asthma, and nasal polyposis (NP) treated benralizumab ANDHI trial. A post hoc assessment of effects on SNOT-22 response asthma efficacy measures these conducted for further characterization safety severe NP.Adults who had experienced ≥2 prior-year exacerbations despite high-dosage inhaled corticosteroid plus additional controller[s] were randomized to 24 weeks or placebo. Patients physician-diagnosed chronic rhinosinusitis NP any severity ongoing at baseline consented participate included current substudy population. Effect symptoms assessed by SNOT-22, an least 8.9 defined as clinically significant (responder). Effects outcomes means annualized exacerbation rate (AER), St. George's Respiratory Questionnaire (SGRQ) total score, forced expiratory volume one second (FEV1 ), Asthma Control Questionnaire-6 (ACQ-6). All p-values nominal.Of population (n = 656), 23% 153) participated 96 benralizumab; n 57 placebo). 50% female, mean age 53 years, AER 3.3; pre-bronchodilator FEV1 55% predicted; median blood eosinophil count ​= 510 cells/µl. For high scores (>30), treatment improved measured from Week compared placebo (Week 24: -10.44 [p .0176]). Percentage responders greater vs. (71.3% 45.5%; p .0036), effect enhanced (>30). 69% reduction (0.77 2.47; < .0001) improvements SGRQ score (-16.7), (+0.32 L), ACQ-6 (-0.88) (p .0001). Benralizumab well-tolerated. Frequency adverse events (AEs) similar (76.0%) (73.7%) groups. Most common AEs (frequency ≥5%) reported a frequency headache, sinusitis, pyrexia, influenza.These data demonstrated profile NP, outcomes.